Your browser is no longer supported. Please, upgrade your browser.
CTLT [NYSE]
Catalent, Inc.
IndexS&P 500 P/E61.10 EPS (ttm)1.78 Insider Own0.40% Shs Outstand170.23M Perf Week-0.69%
Market Cap18.56B Forward P/E33.38 EPS next Y3.25 Insider Trans-89.25% Shs Float169.45M Perf Month4.45%
Income291.50M PEG3.83 EPS next Q0.74 Inst Own- Short Float1.42% Perf Quarter-5.95%
Sales3.46B P/S5.36 EPS this Y20.60% Inst Trans3.24% Short Ratio2.27 Perf Half Y17.82%
Book/sh20.68 P/B5.25 EPS next Y15.76% ROA3.80% Target Price133.90 Perf Year88.07%
Cash/sh4.88 P/C22.27 EPS next 5Y15.97% ROE10.00% 52W Range56.70 - 127.68 Perf YTD4.38%
Dividend- P/FCF- EPS past 5Y-8.30% ROI5.70% 52W High-14.40% Beta1.44
Dividend %- Quick Ratio2.00 Sales past 5Y11.10% Gross Margin32.30% 52W Low92.75% ATR2.84
Employees13900 Current Ratio2.50 Sales Q/Q26.30% Oper. Margin13.40% RSI (14)53.43 Volatility2.32% 2.60%
OptionableYes Debt/Eq0.88 EPS Q/Q94.80% Profit Margin8.40% Rel Volume0.51 Prev Close108.63
ShortableYes LT Debt/Eq0.86 EarningsFeb 02 BMO Payout0.00% Avg Volume1.06M Price109.29
Recom1.70 SMA202.26% SMA50-0.40% SMA20011.26% Volume71,019 Change0.61%
Dec-10-20Upgrade KeyBanc Capital Markets Sector Weight → Overweight $120
Jun-25-20Initiated Argus Buy $100
Apr-21-20Initiated RBC Capital Mkts Outperform $65
Mar-02-20Initiated Deutsche Bank Hold
Oct-17-19Resumed Stephens Overweight $56
Aug-28-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jun-21-19Upgrade Jefferies Hold → Buy $50 → $62
Apr-16-19Upgrade UBS Neutral → Buy $43 → $54
Nov-07-18Upgrade First Analysis Sec Neutral → Outperform $47 → $43
Oct-09-18Initiated UBS Neutral
Mar-28-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Mar-21-18Upgrade Raymond James Mkt Perform → Outperform
Feb-06-18Downgrade Stephens Overweight → Equal-Weight
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-17Initiated Needham Hold
Sep-08-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Dec-01-16Initiated Goldman Neutral
Oct-20-16Initiated KeyBanc Capital Mkts Overweight $29
Jun-21-16Upgrade Wells Fargo Market Perform → Outperform
Jun-20-16Upgrade BofA/Merrill Neutral → Buy
Apr-19-21 08:30AM  
Apr-13-21 08:59AM  
Apr-12-21 04:49PM  
Apr-07-21 08:00AM  
Apr-06-21 09:00AM  
06:46AM  
06:26AM  
06:24AM  
Mar-31-21 06:52PM  
Mar-29-21 01:58PM  
Mar-25-21 09:50AM  
06:00AM  
Mar-24-21 02:13AM  
Mar-23-21 02:32PM  
11:53AM  
Mar-22-21 07:15AM  
Mar-18-21 02:58AM  
Mar-17-21 08:00PM  
09:37AM  
09:21AM  
Mar-16-21 08:00PM  
Mar-15-21 06:01AM  
Mar-02-21 01:30PM  
Mar-01-21 02:52PM  
02:46PM  
Feb-25-21 12:46PM  
Feb-24-21 04:10PM  
Feb-19-21 04:15PM  
Feb-18-21 01:15PM  
Feb-16-21 04:02PM  
Feb-11-21 11:40AM  
Feb-10-21 04:49PM  
02:26PM  
07:44AM  
01:19AM  
Feb-09-21 12:45PM  
10:03AM  
Feb-03-21 04:30PM  
Feb-02-21 02:30PM  
01:34PM  
08:35AM  
07:37AM  
07:15AM  
Feb-01-21 10:38AM  
10:07AM  
Jan-26-21 12:31PM  
Jan-20-21 08:45AM  
08:33AM  
Jan-18-21 12:10PM  
Jan-16-21 08:00AM  
Jan-14-21 12:34PM  
Jan-13-21 07:25AM  
Jan-11-21 12:41AM  
Jan-06-21 08:55AM  
Jan-05-21 12:45PM  
Dec-28-20 08:32AM  
Dec-24-20 12:00PM  
Dec-15-20 11:45AM  
Dec-11-20 10:54AM  
Dec-10-20 09:30PM  
10:30AM  
Dec-06-20 02:22AM  
Nov-27-20 08:30AM  
Nov-19-20 10:08AM  
Nov-18-20 04:23PM  
Nov-16-20 10:06AM  
Nov-13-20 09:42AM  
Nov-11-20 09:16AM  
Nov-09-20 02:47PM  
Nov-06-20 06:03AM  
Nov-03-20 02:31PM  
09:52AM  
08:35AM  
07:15AM  
Oct-31-20 10:19AM  
Oct-23-20 05:30AM  
Oct-22-20 09:00AM  
Oct-16-20 09:00AM  
Oct-13-20 08:44AM  
08:40AM  
Oct-01-20 07:55AM  
Sep-14-20 09:34AM  
Sep-10-20 09:22AM  
Sep-09-20 12:44PM  
10:14AM  
Sep-08-20 06:28PM  
04:54PM  
04:24PM  
11:20AM  
08:59AM  
08:39AM  
08:39AM  
08:39AM  
08:38AM  
Sep-04-20 07:16PM  
06:11PM  
06:02PM  
Sep-03-20 08:00AM  
Sep-01-20 09:57AM  
09:12AM  
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schmidt Kay ASVP, Technical OperationsMar 22Sale105.771,400148,07813,866Mar 23 07:27 PM
Chiminski John RChair & CEOMar 19Option Exercise42.06183,0247,698,674346,642Mar 22 02:19 PM
Chiminski John RChair & CEOMar 19Sale106.01183,02419,402,784163,618Mar 22 02:19 PM
Fasman Steven LSVP & General CounselMar 18Option Exercise38.7821,647839,44594,954Mar 22 02:20 PM
Chiminski John RChair & CEOMar 18Option Exercise36.0242,2201,520,764205,838Mar 22 02:19 PM
Chiminski John RChair & CEOMar 18Sale105.1642,2204,439,855163,618Mar 22 02:19 PM
Fasman Steven LSVP & General CounselMar 18Sale104.5321,6472,262,77073,307Mar 22 02:20 PM
Joseph WettenySVP & Chief Financial OfficerFeb 16Option Exercise52.565,000262,79954,823Feb 18 09:56 AM
Joseph WettenySVP & Chief Financial OfficerFeb 16Sale124.545,000622,68549,823Feb 18 09:56 AM
Joseph WettenySVP & Chief Financial OfficerFeb 08Sale113.734,604523,61349,823Feb 10 09:05 AM
Whitlow Ricci SPresident, CSSJan 21Sale118.8569282,2442,576Jan 25 07:17 AM
Flynn KarenPres. Biologics & CCOJan 11Sale112.302,478278,27934,544Jan 11 07:12 PM
Gunther ScottSVP, Quality & Reg. AffairsJan 06Sale104.78616,39216,509Jan 07 07:04 AM
Schmidt Kay ASVP, Technical OperationsJan 04Sale104.42737,62315,266Jan 05 09:47 PM
Whitlow Ricci SPresident, CSSJan 04Sale104.42838,6673,268Jan 05 09:47 PM
Joseph WettenySVP & Chief Financial OfficerJan 04Sale104.4217217,96054,427Jan 05 09:46 PM
Maselli AlessandroPresident & COOJan 04Sale104.4214815,45419,618Jan 05 09:46 PM
Pravda RicardoSVP & Chief HR OfficerJan 04Sale104.42788,14513,870Jan 05 09:46 PM
Gennadios AristipposPresident Softgel & Oral TechJan 04Sale104.4211011,48651,315Jan 05 09:45 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Jan 04Sale104.4212613,15717,076Jan 05 09:45 PM
Gunther ScottSVP, Quality & Reg. AffairsJan 04Sale104.4212012,53016,570Jan 05 09:45 PM
Arnold JonathanPres. Oral & Specialty Deliv.Jan 04Sale104.42161,67138,602Jan 05 09:44 PM
Fasman Steven LSVP & General CounselJan 04Sale104.4218919,73573,307Jan 05 09:44 PM
Flynn KarenPres. Biologics & CCOJan 04Sale104.429910,33837,022Jan 05 09:44 PM
Gennadios AristipposPresident Softgel & Oral TechDec 21Option Exercise32.6813,662446,52661,151Dec 23 07:19 AM
Gennadios AristipposPresident Softgel & Oral TechDec 21Sale102.8413,6621,405,04451,425Dec 23 07:19 AM
Zippelius PeterDirectorNov 23Sale99.265,392,280535,237,7130Nov 25 05:53 PM
Fasman Steven LSVP & General CounselNov 11Sale100.992,425244,90173,496Nov 12 12:21 PM
Fasman Steven LSVP & General CounselOct 14Option Exercise26.1815,025393,42687,460Oct 16 06:13 PM
Fasman Steven LSVP & General CounselOct 14Sale93.095,510512,93475,921Oct 16 06:13 PM
Schmidt Kay ASVP, Technical OperationsOct 14Sale93.152,985278,04515,764Oct 16 06:13 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Oct 12Sale94.991,680159,58317,202Oct 13 08:24 AM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Option Exercise30.8439,3421,213,36477,960Oct 09 03:24 PM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Sale91.5015,9281,457,41238,618Oct 09 03:24 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Option Exercise36.027,347264,63926,249Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Option Exercise29.90138,1354,130,817404,337Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Sale86.01182,23115,673,809173,618Oct 05 07:55 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Sale85.484,359372,60816,690Oct 05 07:55 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Sep 02Sale89.502,250201,37818,882Sep 08 01:21 PM
LUCIER GREGORY TDirectorJul 30Sale90.0924,0002,162,16016,921Aug 03 12:02 PM
Gunther ScottSVP, Quality & Reg. AffairsJun 29Sale72.002,824203,31813,365Jul 01 06:15 PM
Gennadios AristipposPresident Softgel & Oral TechJun 25Option Exercise27.9722,255622,54159,736Jun 29 06:54 PM
Gennadios AristipposPresident Softgel & Oral TechJun 25Sale73.008,325607,72544,520Jun 29 06:54 PM